 Health Canada has approved BeiGene Ltd NASDAQ: BGNE Brukinsa zanubrutinib for the treatment of mantle cell lymphoma MCL in adult patients who have received at least one prior therapy. This is the second approval for Brukinsa in Canada, following its initial approval in March for adult patients with Waldenströms macroglobulinemia WM. 